Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]

View source ↗

Summary

The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Multiple Myeloma
• Small Lymphocytic Lymphoma

Drugs mentioned

• BMF-219 (covalent menin inhibitor)

Snippet

Sponsor: Biomea Fusion Inc. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED